Shattuck Labs (NASDAQ:STTK) Receives “Neutral” Rating from HC Wainwright

Shattuck Labs (NASDAQ:STTK)‘s stock had its “neutral” rating restated by HC Wainwright in a research note issued on Friday,Benzinga reports.

Several other research analysts have also commented on STTK. Citigroup lowered Shattuck Labs from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $8.00 to $2.00 in a report on Wednesday, October 2nd. Evercore ISI raised shares of Shattuck Labs to a “strong-buy” rating in a research note on Wednesday, October 2nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.67.

Shattuck Labs Trading Up 12.3 %

Shares of NASDAQ STTK opened at $1.37 on Friday. The stock has a market cap of $65.39 million, a PE ratio of -0.74 and a beta of 1.85. Shattuck Labs has a 12-month low of $1.07 and a 12-month high of $11.76. The company has a 50-day moving average of $2.13 and a 200 day moving average of $4.34.

Insider Buying and Selling

In other news, CEO Taylor Schreiber purchased 36,500 shares of the stock in a transaction on Monday, October 7th. The stock was bought at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the acquisition, the chief executive officer now directly owns 71,002 shares of the company’s stock, valued at approximately $85,912.42. The trade was a 105.79 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Shattuck Labs

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Shattuck Labs by 38.2% in the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock valued at $16,270,000 after buying an additional 502,860 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Shattuck Labs by 83.1% in the second quarter. Renaissance Technologies LLC now owns 392,010 shares of the company’s stock valued at $1,513,000 after acquiring an additional 177,910 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Shattuck Labs by 209.7% during the second quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock worth $857,000 after purchasing an additional 150,340 shares during the last quarter. Pinnacle Associates Ltd. increased its position in shares of Shattuck Labs by 15.0% during the second quarter. Pinnacle Associates Ltd. now owns 599,423 shares of the company’s stock worth $2,314,000 after purchasing an additional 78,177 shares in the last quarter. Finally, Villere ST Denis J & Co. LLC lifted its holdings in shares of Shattuck Labs by 83.7% in the 3rd quarter. Villere ST Denis J & Co. LLC now owns 132,600 shares of the company’s stock valued at $463,000 after purchasing an additional 60,400 shares during the last quarter. 58.74% of the stock is owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.